Fig. 5
From: LXR agonist improves peripheral neuropathy and modifies PNS immune cells in aged mice
Activation of LXRs increases lipid efflux. A Percentage macrophage population and phenotypes in the DRG of 24-month-old mice treated with and without LXRs agonist GW3965 (n = 6–9/group). B Percentage macrophage population and phenotypes in the SN of 24-month-old mice treated with and without LXRs agonist GW3965 (n = 6–9/group). C mRNA expression of LXRs target genes in the sorted CD45 + CD11B + cells from the SN of 24-month-old mice treated with and without LXRs agonist GW3965 (n = 8/group). D Cholesterol content in the sorted CD45 + CD11B + cells from the SN of 24-month-old mice treated with and without LXRs agonist GW3965 (n = 8/group). E Percentage oxLDL positive cells from macrophages treated with and without LXRs agonist GW3965 (n = 3 experiments in triplicate). F oxLDL relative intensity in oxLDL positive cells from macrophages treated with and without LXRs agonist GW3965 (n = 50 cells/group). G Representative images of oxLDL positive cells from macrophages treated with and without LXRs agonist GW3965. Arrows represent macrophages with oxLDL staining (oxLDL-red, nucleus-DAPI/blue) and arrowheads represent macrophages without oxLDL staining. All data are Mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005